News
How New Oral Immunology Wins At Bristol Myers Squibb (BMY) Have Changed Its Investment Story
8+ hour, 41+ min ago (338+ words) Earlier this month, Bristol Myers Squibb reported positive interim Phase 3 SUCCESSOR-2 results for oral mezigdomide in relapsed or refractory multiple myeloma and secured U.S. FDA approval for Sotyktu as the first TYK2 inhibitor to treat adults with active psoriatic arthritis. Together, these…...
Bristol Myers (BMY) Q4 2025 Earnings Transcript
1+ mon, 1+ week ago (1194+ words) Thursday, Feb. 5, 2026 at 8 a.m. ET Board Chair and Chief Executive Officer " Christopher Boerner Chief Financial Officer " David Elkins Chief Commercialization Officer " Adam Lenkowsky Chief Medical Officer and Head of Global Drug Development " Cristian Massacesi Vice President, Investor Relations " Chuck Triano Finally,…...
Bristol-Myers Squibb (NYSE:BMY) Reports Strong Q4 CY2025
1+ mon, 1+ week ago (733+ words) Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) announced better-than-expected revenue in Q4 CY2025, with sales up 1.4% year on year to $12.5 billion. The company's full-year revenue guidance of $46.75 billion at the midpoint came in 5.7% above analysts' estimates. Its non-GAAP profit of $1.26 per share…...
Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2025
1+ mon, 1+ week ago (123+ words) Bristol Myers Squibb (NYSE: BMY) today reported fourth quarter and full-year 2025 financial results. Visit the company's Investor Relations website at to view the detailed fourth quarter and ... Oops, something went wrong Prediction markets are now on Yahoo Finance Bristol Myers…...
Assessing Bristol Myers Squibb (BMY) Valuation As Shares Gain And Profitability Narrative Evolves
2+ mon, 1+ week ago (561+ words) Bristol-Myers Squibb (BMY) has been drawing attention after its shares closed at $56.72, leaving investors weighing how recent price moves and mixed growth metrics might fit into a broader long term thesis. See our latest analysis for Bristol-Myers Squibb. The recent…...
Bristol-Myers (BMY) Offers Eliquis Free to Medicaid Patients Under New Pricing Pact
2+ mon, 3+ week ago (359+ words) Bristol-Myers Squibb Company (NYSE:BMY) is included among the Best Stocks for a Dividend Achievers List. Several of the largest US and European drugmakers struck agreements with President Donald Trump on December 19 to voluntarily lower the prices of certain medicines....
Manulife Investment Management Honoured as 2025 Best Asset Manager for Institutional Investors in Canada by Crisil Coalition Greenwich
2+ mon, 3+ week ago (344+ words) Manulife Investment Management (Manulife IM), a company of Manulife Wealth & Asset Management, announced today that it has been recognized as a "2025 Best Asset Manager for Institutional Investors in Canada" by Crisil Coalition Greenwich.1 This accolade recognizes Manulife IM's dedication to servicing…...
Great week for Bristol-Myers Squibb Company (NYSE:BMY) institutional investors after losing 0.8% over the previous year
2+ mon, 4+ week ago (312+ words) Institutions' substantial holdings in Bristol-Myers Squibb implies that they have significant influence over the company's share price A total of 24 investors have a majority stake in the company with 50% ownership Every investor in Bristol-Myers Squibb Company (NYSE:BMY) should be…...
Bristol Myers Squibb Announces Agreement with U.S. Government to Improve Affordability and Access to Critical Medicines for Americans
2+ mon, 4+ week ago (786+ words) Agreement Provides Tariff Relief for a 3-Year Period As part of the agreement, BMS will address the Administration's four priority areas: Make Eliquis available to Medicaid for free starting on January 1, 2026, lowering costs for patients and the healthcare system. Contribute…...
Bristol Myers Squibb Canada Welcomes Positive CDA Recommendation for OPDIVO® Plus YERVOY® as First-Line Treatment for MSI-H/dMMR Metastatic Colorectal Cancer
3+ mon, 9+ hour ago (630+ words) Bristol Myers Squibb Canada (BMS) today announced that Canada's Drug Agency (CDA-AMC) has issued a positive reimbursement recommendation for OPDIVO" (nivolumab) in combination with YERVOY" (ipilimumab) for the first-line treatment of adult patients with unresectable or metastatic microsatellite instability-high (MSI-H)…...